UNITED STATES                     SEC File Number

                  SECURITIES AND EXCHANGE COMMISSION             000-17788

                        Washington, D.C. 20549

                              FORM 12b-25                                   

                      NOTIFICATION OF LATE FILING

(Check One)    Form 10-K  __ Form 20-F __ Form 11-K   X  Form 10-Q

            __ Form N-SAR  __ Form N-CSR

               For Period Ended: September 30, 2010

                 [  ]     Transition Report on Form 10-K

                 [  ]     Transition Report on Form 20-F

                 [  ]     Transition Report on Form 11-K

                 [  ]     Transition Report on Form 10-Q

                 [  ]     Transition Report on Form N-SAR

                  For the Transition Period Ended:________________________

READ ATTACHED INSTRUCTION SHEET BEFORE PREPARING FORM.  PLEASE PRINT OR TYPE

Nothing in the form shall be construed to imply that the Commission has

verified any information contained herein.

If the notification relates to a portion of the filing checked above,

identify the Item(s) to which the notification relates:

--------------------------------------------------------------------------

PART I - REGISTRANT INFORMATION

Laxai Pharma, Ltd.

--------------------------------------------------------------------------

Full Name of Registrant

NexGen Biofuels, Ltd.

--------------------------------------------------------------------------

Former Name if Applicable

8905 Regents Park Drive, Suite 210

--------------------------------------------------------------------------

Address of Principal Executive Office (STREET AND NUMBER)

Tampa, Florida  33647

--------------------------------------------------------------------------

City, State and Zip Code

PART II - RULES 12b-25(b) and (c)

If the subject report could not be filed without unreasonable effort or

expense and the registrant seeks relief pursuant to Rule 12b-25(b), the

following should be completed.  (Check box if appropriate)

         (a)     The reasons described in reasonable detail in Part III of

__               this form could not be eliminated without unreasonable

                 effort or expense;

         (b)     The subject annual report, semi-annual report, transition

X_               report on Form 10-K, Form 20-F, 11-K, Form N-SAR, or

                 Form N-CSR, or portion thereof, will be filed on or

                 before the fifteenth calendar day following the

                 prescribed due date; or the subject quarterly report or

                 transition report on Form 10-Q, or portion thereof, will

                 be filed on or before the fifth calendar day following   

                 the prescribed due date; and

__      (c)      The accountant's statement or other exhibit required by

                 Rule 12b-25(c) has been attached if applicable.

PART III - NARRATIVE

State below in reasonable detail the reasons why the Form 10-K, 20-F, 11-K, 10-Q, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.  (Attach Extra Sheets if Needed)

The Company has encountered a delay in assembling the information required to be included in its Quarterly Report for the period ending September 30, 2010.  The Company expects to file its September 30, 2010, Form 10-Q Quarterly Report with the U.S. Securities and Exchange Commission within 5 calendar days of the prescribed due date.

PART IV - OTHER INFORMATION

(1)      Name and telephone number of person to contact in regard to this

         Notification.

          Richard W. Jones, Esq.       (770)                804-0500

         ------------------------     -----------        -----------------

                (Name)               (Area Code)        (Telephone Number)

(2)      Have all other periodic reports required under Section 13 or

         15(d) of the Securities Exchange Act of 1934 or Section 30 of the

         Investment Company Act of 1940 during the preceding 12 months or

         or such shorter period that the registrant was required to file

         such reports been filed?  If answer is no identify report(s).  

         X Yes   __ No

(3)      Is it anticipated that any significant change in results of

         operations from the corresponding period for the last fiscal year

         will be reflected by the earnings statements to be included in

         the subject report or portion thereof? ___  Yes    _X__  No

         If so, attach an explanation of the anticipated change, both

         narratively and quantitatively, and, if appropriate, state the

         reasons why a reasonable estimate of the results cannot be made.

--------------------------------------------------------------------------

                           LAXAI PHARMA, LTD.

             ------------------------------------------------------

               (Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned

hereunto duly authorized.

                                        LAXAI PHARMA, LTD.

Date:  November 10, 2010                By:  /s/ J. Ram Ajjarapu

                                       ------------------------------

                                        J. Ram Ajjarapu, President

2